JO
ATOS icon

John Overdeck’s Atossa Therapeutics ATOS Stock Holding History

John Overdeck’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,563
Closed -$13.8K – 4576
2025
Q4 		$13.8K Buy
+1,563
New +$19.8K ﹤0.01% 4017
2025
Q1 		– Sell
-5,989
Closed -$84.8K – 3196
2024
Q4 		$84.8K Sell
5,989
-426
-7% -$8.32K ﹤0.01% 2988
2024
Q3 		$146K Sell
6,415
-5,771
-47% -$116K ﹤0.01% 2848
2024
Q2 		$218K Buy
12,186
+9,972
+450% +$221K ﹤0.01% 2707
2024
Q1 		$59.8K Sell
2,214
-8,541
-79% -$137K ﹤0.01% 2875
2023
Q4 		$142K Sell
10,755
-841
-7% -$9.07K ﹤0.01% 2900
2023
Q3 		$128K Buy
11,596
+7,720
+199% +$112K ﹤0.01% 2717
2023
Q2 		$73.3K Sell
3,876
-407
-10% -$4.93K ﹤0.01% 2784
2023
Q1 		$46.6K Sell
4,283
-472
-10% -$5.26K ﹤0.01% 2767
2022
Q4 		$37.7K Sell
4,755
-4,237
-47% -$48.7K ﹤0.01% 2620
2022
Q3 		$112K Buy
8,992
+3,943
+78% +$57.3K ﹤0.01% 2214
2022
Q2 		$83K Sell
5,049
-32,184
-86% -$507K ﹤0.01% 2289
2022
Q1 		$698K Sell
37,233
-120,847
-76% -$2.46M ﹤0.01% 1867
2021
Q4 		$3.79M Buy
158,080
+152,037
+2,516% +$5.56M 0.01% 1377
2021
Q3 		$295K Buy
6,043
+5,038
+501% +$293K ﹤0.01% 3682
2021
Q2 		$95K Buy
+1,005
New +$53.2K ﹤0.01% 3902
2020
Q4 		– Sell
-2,796
Closed -$102K – 3321
2020
Q3 		$102K Buy
+2,796
New +$134K ﹤0.01% 2932

Other funds holding ATOS

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

John Overdeck's ATOS Position: Q1 2026 in Review

John Overdeck sold out of Atossa Therapeutics (ATOS) in Q1 2026, closing a stake of 1,563 shares — an estimated $13.8K sold.

John Overdeck first reported a position in ATOS in Q3 2020 and held it in 17 quarters. The position peaked at $3.79M in Q4 2021. 33 funds tracked by Wall St. Rank hold ATOS as of Q1 2026.

  • John Overdeck reported no remaining Atossa Therapeutics position as of Q1 2026 after selling out during the quarter.
  • John Overdeck sold 1,563 Atossa Therapeutics shares in Q1 2026, an estimated $13.8K.
  • John Overdeck first reported a position in Atossa Therapeutics in Q3 2020 and held it in 17 quarters.
  • John Overdeck's Atossa Therapeutics position peaked at $3.79M in Q4 2021.
  • 33 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.